Quick Sequential Organ Failure Assessment (qSOFA) combined with soluble urokinase plasminogen activator receptor (suPAR) for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial
- prematurely ended
Authors' conclusion
Combining qSOFA 1 with the biomarker suPAR improves its prognostic performance for unfavorable outcome and can help decision for earlier treatment.
Study context
- Population
- Consecutive emergency department (ED) admissions with suspected infection, qSOFA 1 and suPAR ≥ 12 ng/mLRandomized controlled trial (RCT) enrolled
- Participants
- 91 admissions
- Comparison
- Single infusion of meropenem vs placebo
- Meropenemn = 44
- Placebon = 47reference
- Primary endpoint
- Early deterioration (≥1-point increase of admission SOFA score)
- Follow-up
- First 24 h
Methodological detailsdouble-blind, prospective cohort part, Nov 2018 to Dec 2020
- Double-blind
- Prospective cohort part
- Nov 2018 to Dec 2020
Primary result
As reported in the abstract
Difference (CI)
Placebo vs Meropenem
24.5%(5.9–40.8)
Odds ratio (CI)
Meropenem vs Placebo
0.14(0.04–0.50)
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| 28-day mortality, qSOFA = 1 and suPAR ≥ 12 ng/mL vs qSOFA = 1 and suPAR < 12 ng/mL (prospective cohort) | 2.98 (2.11–3.96) | |
| 0.20.5125Hazard ratio (log scale) |
Median change of Sequential Organ Failure Assessment (SOFA) score (post hoc analysis) · 72 and 96 h
- Significant median changes of SOFA score after 72 h
- 0
- Significant median changes of SOFA score after 96 h
- - 1
- Post hoc
Original publication
qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial. Crit Care. Published 6 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →